Dupilumab in Adults and Adolescents with Eosinophilic EsophagitisEvan S. Dellon, Arsalan Shabbir, Bolanle Akinlade et al.|New England Journal of Medicine|2022Cited by 452
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of AgeMirna Chehade, Jennifer Maloney, Evan S. Dellon et al.|New England Journal of Medicine|2024Cited by 107
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialMarc E. Rothenberg, Arsalan Shabbir, Evan S. Dellon et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 100
Dupilumab Improves Clinical and Histologic Aspects of Disease in Adult and Adolescent Patients With Eosinophilic Esophagitis at Week 24: Results from Part B of the 3-Part LIBERTY EoE TREET StudyMarc E. Rothenberg, Arsalan Shabbir, Evan S. Dellon et al.|Journal of Allergy and Clinical Immunology|2022Cited by 12
Dupilumab Improves Health-Related Quality of Life and a Range of Symptoms in Patients With Eosinophilic EsophagitisJonathan M. Spergel, Eilish McCann, Mirna Chehade et al.|The American Journal of Gastroenterology|2024Cited by 12